LPL Financial LLC Acquires 55,410 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

LPL Financial LLC grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 36.6% during the 4th quarter, Holdings Channel reports. The fund owned 207,003 shares of the biopharmaceutical company’s stock after buying an additional 55,410 shares during the period. LPL Financial LLC’s holdings in Halozyme Therapeutics were worth $9,897,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of HALO. Smartleaf Asset Management LLC increased its stake in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares in the last quarter. Louisiana State Employees Retirement System increased its position in Halozyme Therapeutics by 0.6% in the fourth quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock worth $1,688,000 after buying an additional 200 shares in the last quarter. State of New Jersey Common Pension Fund D increased its position in Halozyme Therapeutics by 0.6% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock worth $2,279,000 after buying an additional 302 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 322 shares during the period. Finally, Nations Financial Group Inc. IA ADV grew its stake in shares of Halozyme Therapeutics by 2.4% during the 4th quarter. Nations Financial Group Inc. IA ADV now owns 14,062 shares of the biopharmaceutical company’s stock valued at $672,000 after acquiring an additional 328 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the transaction, the director now owns 38,611 shares of the company’s stock, valued at $2,173,799.30. This represents a 11.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Michael J. Labarre sold 1,697 shares of the company’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,200 shares of company stock worth $1,786,668 over the last three months. 2.90% of the stock is owned by insiders.

Analyst Ratings Changes

HALO has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Piper Sandler upped their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Wells Fargo & Company decreased their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Finally, Benchmark reissued a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $62.78.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $59.77 on Friday. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $66.00. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The firm’s fifty day moving average is $59.82 and its 200 day moving average is $54.93. The company has a market cap of $7.38 billion, a price-to-earnings ratio of 17.43, a PEG ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.